Feb 8 (Reuters) – AstraZeneca said on Thursday it expects revenue and profit to rise in 2024, as the company banks on strong uptake of its RSV vaccine in infants and sustained demand for its drugs for cancer and rare blood diseases.
Strong sales of AstraZeneca’s cancer treatments and rare disease drugs, combined with healthy demand in emerging markets, have fueled the company’s growth for nearly a decade.
The London-listed drugmaker said it expects total revenue and earnings per share (EPS) to increase by between 10% and 15%.
For 2023, AstraZeneca reported revenue of $45.81 billion (€42.47 billion) and EPS of $7.26 per share.
For the fourth quarter, the group reported EPS of $1.45 per share on total revenue of $12.02 billion. Analysts were expecting $1.5 billion and $12.01 billion, respectively, according to a consensus compiled by the company. (Reporting by Eva Mathews in Bangalore; French version by Gaëlle Sheehan, edited by Blandine Hénault)
©2024 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.